Literature DB >> 34957569

All-optical monitoring of excitation-secretion coupling demonstrates that SV2A functions downstream of evoked Ca2+ entry.

Mazdak M Bradberry1,2, Edwin R Chapman1.   

Abstract

SV2A, an essential transporter-like synaptic vesicle protein, is a major target for antiepileptic drugs and a receptor for clostridial neurotoxins including Botox. While SV2A is required for normal levels of evoked neurotransmitter release, the mechanism underlying this role remains unclear. Here, we introduce a new chemogenetic approach for all-optical monitoring of excitation-secretion coupling, and we demonstrate its use in characterizing the SV2A knockout (KO) phenotype in cultured hippocampal neurons. This method employs the HaloTag system to target a robust small-molecule Ca2+ indicator, JF646 -BAPTA, to the presynaptic compartment. The far-red fluorescence of this indicator enables multiplexing with the fluorescent glutamate sensor iGluSnFR for detection of presynaptic Ca2+ influx and glutamate release at the same axonal boutons. Evoked glutamate release probability was reduced in SV2A KO neurons without a change in presynaptic Ca2+ entry, suggesting that SV2A supports vesicle fusion by increasing the functional availability, or efficiency, of the Ca2+ -regulated membrane fusion machinery. KEY POINTS: One of the most prescribed antiepileptic medications, levetiracetam, acts by binding a protein of uncertain molecular function. This transporter-like protein, SV2A, is trafficked to synaptic vesicles and acts to support neurotransmitter release, but the mechanism underlying this function has not been determined In this study, we sought to establish whether SV2A changes Ca2+ signalling at nerve terminals, which is a key regulatory system for synaptic vesicle exocytosis. To do so, we adapted new chemogenetic tools to perform all-optical measurements of presynaptic Ca2+ and glutamate release in neurons lacking SV2A. Our measurements showed that loss of SV2A reduces glutamate release without reducing Ca2+ influx at hippocampal nerve terminals, demonstrating that SV2A increases the likelihood that Ca2+ will trigger synaptic vesicle fusion.
© 2021 The Authors. The Journal of Physiology © 2021 The Physiological Society.

Entities:  

Keywords:  SV2A; antiepileptic; exocytosis; levetiracetam; presynaptic Ca2+; synaptic vesicle

Mesh:

Year:  2022        PMID: 34957569      PMCID: PMC8810609          DOI: 10.1113/JP282601

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  43 in total

1.  Synaptic vesicle protein 2 enhances release probability at quiescent synapses.

Authors:  Kenneth L Custer; Naola S Austin; Jane M Sullivan; Sandra M Bajjalieh
Journal:  J Neurosci       Date:  2006-01-25       Impact factor: 6.167

2.  SV2 is the protein receptor for botulinum neurotoxin A.

Authors:  Min Dong; Felix Yeh; William H Tepp; Camin Dean; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Science       Date:  2006-03-16       Impact factor: 47.728

3.  SNARE protein recycling by αSNAP and βSNAP supports synaptic vesicle priming.

Authors:  Andrea Burgalossi; Sangyong Jung; Guido Meyer; Wolf J Jockusch; Olaf Jahn; Holger Taschenberger; Vincent M O'Connor; Tei-ichi Nishiki; Masami Takahashi; Nils Brose; Jeong-Seop Rhee
Journal:  Neuron       Date:  2010-11-04       Impact factor: 17.173

Review 4.  Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Authors:  Henrik Klitgaard; Alain Matagne; Jean-Marie Nicolas; Michel Gillard; Yves Lamberty; Marc De Ryck; Rafal M Kaminski; Karine Leclercq; Isabelle Niespodziany; Christian Wolff; Martyn Wood; Jonas Hannestad; Sophie Kervyn; Benoit Kenda
Journal:  Epilepsia       Date:  2016-02-26       Impact factor: 5.864

5.  Synaptotagmin increases the dynamic range of synapses by driving Ca²+-evoked release and by clamping a near-linear remaining Ca²+ sensor.

Authors:  Olexiy Kochubey; Ralf Schneggenburger
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

6.  Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin.

Authors:  A E Schivell; R H Batchelor; S M Bajjalieh
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

7.  SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.

Authors:  Rafal M Kaminski; Alain Matagne; Karine Leclercq; Michel Gillard; Philippe Michel; Benoit Kenda; Patrice Talaga; Henrik Klitgaard
Journal:  Neuropharmacology       Date:  2007-12-08       Impact factor: 5.250

8.  Computer control of microscopes using µManager.

Authors:  Arthur Edelstein; Nenad Amodaj; Karl Hoover; Ron Vale; Nico Stuurman
Journal:  Curr Protoc Mol Biol       Date:  2010-10

9.  Sensitive red protein calcium indicators for imaging neural activity.

Authors:  Hod Dana; Boaz Mohar; Yi Sun; Sujatha Narayan; Andrew Gordus; Jeremy P Hasseman; Getahun Tsegaye; Graham T Holt; Amy Hu; Deepika Walpita; Ronak Patel; John J Macklin; Cornelia I Bargmann; Misha B Ahrens; Eric R Schreiter; Vivek Jayaraman; Loren L Looger; Karel Svoboda; Douglas S Kim
Journal:  Elife       Date:  2016-03-24       Impact factor: 8.140

10.  Acute disruption of the synaptic vesicle membrane protein synaptotagmin 1 using knockoff in mouse hippocampal neurons.

Authors:  Jason D Vevea; Edwin R Chapman
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

View more
  1 in total

Review 1.  Synaptic Vesicle Glycoprotein 2A: Features and Functions.

Authors:  Rachele Rossi; Shokouh Arjmand; Simone Larsen Bærentzen; Albert Gjedde; Anne M Landau
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 5.152

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.